OTCMKTS:ASCLF

Ascletis Pharma (ASCLF) Stock Forecast, Price & News

$0.34

-0.03 (-8.57%)

(As of 05/18/2023)

Compare

Today's Range: $0.34
▼
$0.34
50-Day Range: $0.31
▼
$0.62
52-Week Range: $0.31
▼
$0.62

Volume: 1,000 shs
Average Volume: 2,670 shs
Market Capitalization: N/A

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Profile Chart Competitors Headlines Short Interest

About Ascletis Pharma (OTCMKTS:ASCLF) Stock

Ascletis Pharma Inc., a biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China and internationally. The company offers Ritonavir oral tablet, a pharmacokinetic booster of various oral antiviral drugs targeting viral proteases and a component of the approved oral antiviral drug Paxlovid; ASCLEVIR and GANOVO for the treatment of Hepatitis C virus. It is also developing ASC22 for treating chronic hepatitis B (CHB) and human immunodeficiency virus functional cure; ASC42 for chronic hepatitis B functional cure; ASC10 and ASC11 to treat COVID-19; ASC40, ASC41, ASC42, ASC43F FDC, ASC44F FDC, and ASC45F FDC for non-alcoholic steatohepatitis; and ASC42 for the treatment of primary biliary cholangitis. In addition, the company is developing ASC40 to treat recurrent glioblastoma, drug resistant breast cancer, and KRAS mutant non-small cell lung cancer; ASC61 and ASC63 for advanced solid tumors; ASC60 to treat solid tumors; and ASC40 for the treatment of acne, Ascletis Pharma Inc. was founded in 2013 and is headquartered in Hangzhou, the People's Republic of China.

Receive ASCLF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ascletis Pharma and its competitors with MarketBeat's FREE daily newsletter.

ASCLF Stock News Headlines

May 8, 2023 | markets.businessinsider.com

Ascletis Pharma: China Approves To Conduct Phase IIa Clinical Trial For ASC10 To Treat RSV Infection

May 8, 2023 | finance.yahoo.com

Ascletis Announces China NMPA Approval of Conducting a Phase IIa Clinical Trial for ASC10 to Treat Respiratory Syncytial Virus Infection

May 29, 2023 | Behind the Markets (Ad)

"Chilling War Games Show US Forces Crushed" – FOX NEWS

=== BREAKING === "Chilling War Games Show US Forces Crushed" - FOX NEWS After losing to China in repeated war games, U.S. military to spend billions on new "living missile" for armed forces. Investors stand to reap 35,960% on shares of small defense contractor that makes powerful new weapon. Get the name of the stock here >>>

May 2, 2023 | finance.yahoo.com

Ascletis Announces ASC40, a First-in-Class, Once-Daily Oral FASN Inhibitor, Achieved Endpoints in Phase II Clinical Trial for Acne

May 1, 2023 | americanbankingnews.com

Ascletis Pharma Inc. (OTCMKTS:ASCLF) Sees Significant Decrease in Short Interest

February 27, 2023 | finance.yahoo.com

Ascletis (1672.HK) Included in the Hang Seng Hong Kong-Listed Biotech Index

January 31, 2023 | finance.yahoo.com

Ascletis Announces U.S. FDA Approval of Conducting a Phase IIa Clinical Trial for ASC10 to Treat Respiratory Syncytial Virus Infection

January 26, 2023 | finance.yahoo.com

Ascletis Announces IND Approval of Oral Viral Polymerase Inhibitor ASC10 for Monkeypox Indication by China NMPA

May 29, 2023 | Behind the Markets (Ad)

"Chilling War Games Show US Forces Crushed" – FOX NEWS

January 17, 2023 | msn.com

Supply enters ritonavir tablets supply agreement with Simcere

January 16, 2023 | finance.yahoo.com

Ascletis Announces Entering into a Supply Agreement of Ritonavir Tablets with Simcere

January 15, 2023 | finance.yahoo.com

Ascletis Announces Dosing of 4 Healthy Subjects of the First Cohort in Multiple-Dose Escalation Phase I Clinical Trial of Oral 3CLpro Inhibitor ASC11 for COVID-19

January 3, 2023 | msn.com

Viking Therapeutics sues Ascletis Pharma for stealing trade secrets

December 20, 2022 | finance.yahoo.com

Ascletis' NASH Drug ASC41(THRβ) Phase II Enrollment is Progressing as Planned

December 19, 2022 | finance.yahoo.com

Ascletis Announces Notice of Issuance of the U.S. Patent for Oral Viral Polymerase Inhibitor ASC10 and Its Derivatives

December 12, 2022 | markets.businessinsider.com

Ascletis Announces Positive Early-Stage Results Of Oral RdRp Inhibitor ASC10 For COVID-19

December 12, 2022 | finance.yahoo.com

Ascletis Announces Positive Phase I Clinical Results of Oral RdRp Inhibitor ASC10 for COVID-19

December 7, 2022 | marketwatch.com

Ascletis Pharma Shares Gain After Covid-19 Drug Approved for Clinical Trial

December 7, 2022 | markets.businessinsider.com

Ascletis Pharma Announces IND Approval For ASC11 In China - Quick Facts

December 7, 2022 | seekingalpha.com

Ascletis gets Chinese drug regulator nod to start trial of oral COVID therapy

November 30, 2022 | finance.yahoo.com

Ascletis Announces Completion of 180 Patient Enrollment for Phase II Clinical Trial of FASN Inhibitor ASC40 for Acne

November 23, 2022 | markets.businessinsider.com

Ascletis Pharma : FDA Approves IND Of Oral 3CLpro Inhibitor ASC11 For COVID-19

November 23, 2022 | finance.yahoo.com

Ascletis Announces IND Approval of Oral 3CLpro Inhibitor ASC11 for COVID-19 by U.S. FDA

November 16, 2022 | finance.yahoo.com

Ascletis Announces IND Approval of Oral PD-L1 Small Molecule Inhibitor ASC61 for Treatment of Advanced Solid Tumors by China NMPA

November 1, 2022 | finance.yahoo.com

Ascletis Announces U.S. IND Filing of Oral 3CLpro Inhibitor ASC11 for COVID-19

October 26, 2022 | finance.yahoo.com

Ascletis Announces U.S. IND Filing of Oral Antiviral ASC10 for Monkeypox Indication

October 10, 2022 | seekingalpha.com

Week In Review: AIM Vaccine Stages $20 Million IPO On Hong Kong Exchange

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive ASCLF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ascletis Pharma and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange: OTCMKTS
Industry: Biotechnology
Sub-Industry: N/A
Sector: Medical
Current Symbol: OTCMKTS:ASCLF
CUSIP: N/A
CIK: N/A
Web: www.ascletis.com
Phone: N/A
Fax: N/A
Employees: 266
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: N/A
Free Float: N/A
Market Cap: N/A
Optionable: Not Optionable
Beta: N/A

Key Executives

Dr. Jinzi Jason Wu (Age 60)
Founder, Chairman & CEO

Dr. Handan He Ph.D. (Age 61)
Chief Scientific Officer

Ms. Hejingdao Wu (Age 49)
Sr. VP of Operations & Exec. Director

Ms. Yuemei Yan (Age 53)
Sr. VP of Clinical Devel. Operations

Dr. Kristjan Sigurdur Gudmundsson (Age 55)
Sr. Consultant & Head of Discovery

Dr. George Zhengzhi Hill (Age 72)
Sr. Consultant & Chief Medical Advisor

Mr. John P. Gargiulo M.B.A.
Chief Bus. Officer

Mr. Ming Fai Chung CPA
Company Sec.

Key Competitors

View All Competitors

ASCLF Stock - Frequently Asked Questions

How have ASCLF shares performed in 2023?: Ascletis Pharma's stock was trading at $0.55 at the start of the year. Since then, ASCLF shares have decreased by 37.4% and is now trading at $0.3445.
View the best growth stocks for 2023 here.
Are investors shorting Ascletis Pharma?: Ascletis Pharma saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 743,300 shares, an increase of 5.4% from the April 30th total of 705,000 shares. Based on an average trading volume of 4,200 shares, the days-to-cover ratio is currently 177.0 days.
View Ascletis Pharma's Short Interest.

What is Ascletis Pharma's stock symbol?: Ascletis Pharma trades on the OTCMKTS under the ticker symbol "ASCLF."
How do I buy shares of Ascletis Pharma?: Shares of ASCLF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Ascletis Pharma's stock price today?: One share of ASCLF stock can currently be purchased for approximately $0.34.
How many employees does Ascletis Pharma have?: The company employs 266 workers across the globe.

This page (OTCMKTS:ASCLF) was last updated on 5/29/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial